The company plans to file in the third quarter of 2013. AcelRx tested its ARX-01 Sufentanil NanoTab patient-controlled analgesia system against intravenous PCA with morphine on 359 adult patients. Initial data shows the NanoTab to be significantly better than intravenous morphine.
While intravenous morphine PCAs are common in hospitals, morphine can cause nausea, vomiting and other opioid-related side effects. It also carries a higher risk of addiction. Rather than morphine, the NanoTab administers sufentanil, another opioid with fewer side effects.
More Articles on Anesthesia:
4 Capabilities of ACO-Ready Anesthesia Groups
Anesthesia Business Consultants to Resell EHR as F1RSTUse
Decision Tree-Based Learning Improves Anesthesia Consumption Predictions
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
